Chandni Radia

Chandni Radia

Auto-generated profile, based on publicly available information

Chandni Radia

King’s College Hospital NHS Foundation Trust , London

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2025 in BMJ Open Gastroenterology
Verified
Journal Article
Open access
PDF file
YDYaa Danso
Yaa Danso
CRChandni Radia
Chandni Radia
AEAlex Elford
Alex Elford
JYJie Han Yeo
Jie Han Yeo
TMThomas Morris
Thomas Morris
CSChristian Selinger
Christian Selinger
Objective: Upadacitinib is the first Janus kinase inhibitor and oral advanced therapy licensed for Crohn’s disease (CD). Following NICE approval in 2023, real-world data on outcomes are limited. The effectiveness and safety of upadacitinib in a cohort of patients with CD was assessed. Methods: A multicentre retrospective cohort analysis across 19 UK hospitals. Adult patients with active CD who started upadacitinib between April 2023 and October 2023 were included. Outcomes were reviewed over 24 weeks. The primary endpoint was clinical remission (Harvey Bradshaw Index (HBI) <4) at 12 and 24 weeks. Biochemical remission (faecal calprotectin <200 μg/g and C-reactive protein ≤5) and endoscopic remission (Simple Endoscopic Score for Crohn’s Disease ≤3) were assessed at the same intervals. Adverse events (AEs) were recorded until 24 weeks or drug withdrawal. Results: 312 patients were included, with a minimum follow-up of 12 weeks. The cohort had difficult-to-treat disease; 64% failing 3 or more biologics, 51% exhibiting penetrating or stricturing disease and 41% requiring prior resection. 50% (113/227) of patients achieved clinical remission at 12 weeks and 45% (77/172) at 24 weeks. Patients with colonic disease had higher remission rates at 24 weeks compared with other disease locations. At 24 weeks, 51 patients (16%) had discontinued upadacitinib. Treatment persistence was 90.3% at 12 weeks and 84.1% at 24 weeks. 28% had AEs, with 18% experiencing serious AEs and 16.6% requiring hospitalisation. Conclusion: This is a large real-world study reporting outcomes in patients with CD treated with upadacitinib. Our data demonstrated good short-term effectiveness and tolerance in a clinically refractory population.

20 August 2025 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
CRChandni Radia
Chandni Radia
YDYaa Danso
Yaa Danso
SRSusan Ritchie
Susan Ritchie
MHMelissa Hale
Melissa Hale
AEAlexander T Elford
Alexander T Elford
KKKlaartje Bel Kok
Klaartje Bel Kok
Background and Aims: Janus kinase inhibitors (JAKi) provide effective treatment for ulcerative colitis (UC), but inadequate response (IR) or intolerance occurs frequently. This study aimed to assess the effectiveness of a second JAKi in a real-world UC cohort. Methods: A retrospective multicenter cohort study encompassing 19 UK hospitals was undertaken. Primary outcome was clinical remission (Simple Clinical Colitis Activity Index/partial Mayo Score ≤ 1) at weeks 8 and 24, based on available assessments. Biochemical (CRP ≤ 5mg/L and fecal calprotectin ≤ 200µg/g) and endoscopic (Ulcerative Colitis Endoscopic Index of Severity/Mayo Endoscopic Subscore ≤ 1) remission were also assessed. Results: A total of 131 patients with active UC were included. The majority (60%) had exposure to ≥3 advanced therapies and 50% required corticosteroids at induction. Clinical remission rates were 59% and 51% at weeks 8 and 24. Biochemical and endoscopic remission rates were 61% and 60% at week 8, and 47% and 32% at week 24. All disease activity parameters significantly reduced by week 8 (P < .001). At week 24 no difference was detected in clinical remission rates between those with primary non-response (42%) or secondary loss of response (52%) to their first JAKi (P = .518). Clinical remission did not differ between upadacitinib (54%) and filgotinib (36%), P = .253. Adverse events occurred in 27% of patients, and serious adverse events in 8%. Conclusions: In this highly refractory cohort with active UC a second JAKi effectively achieved remission following IR to first JAKi. Type of first JAKi failure did not appear to influence clinical remission. No new safety signals were found.

14 April 2023 in Endoscopy
Verified
Journal Article
Closed access
MNM. A. Noreillie
M. A. Noreillie
HAH. Ayubi
H. Ayubi
SJS. Jabak
S. Jabak
OOO. Olabintan
O. Olabintan
CRC. Radia
C. Radia
AHAmyn Haji
Amyn Haji
Text Endoscopic electroporation is a novel technique used in the management of inoperable colorectal and oesophageal cancers. This technique involves the delivery of short electrical pulses to tumour tissues, which transiently increases cell membrane permeability, allowing the passage of calcium ions through the open pores to give a high local cytotoxic effect with minimal adverse systemic effect. In this video we show how this technique is used to treat an inoperable locally advanced obstructing sigmoid adenocarcinoma. Clinical result of this technique has shown excellent safety profile, tumour regression, and marked reduction or cessation of tumour bleeding [1] [2] [3] [4]. Article published online: 14 April 2023 © 2023. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

24 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
CRChandni Radia
Chandni Radia
AKAndrew King
Andrew King
CHChristopher Harlow
Christopher Harlow
AKAmirhosein Kefayat
Amirhosein Kefayat
JYJie Han Yeo
Jie Han Yeo
PPPolychronis Pavlidis
Polychronis Pavlidis
Background: Dye chromoendoscopy (DCE) is the recommended endoscopic modality for dysplasia detection in inflammatory bowel disease (IBD) surveillance, but randomised trials suggest comparable performance with virtual chromoendoscopy (VCE) and high-definition white light endoscopy (WLE). This multicentre UK study evaluated the association between modality and dysplasia detection in routine practice. Methods: We performed a multicentre study across six UK centres, identifying adults with ulcerative colitis (UC), colonic Crohn’s disease (CD), or primary sclerosing cholangitis associated IBD (PSC-IBD) undergoing surveillance colonoscopy between 2019-2024. Outcomes included dysplasia detection rate (DDR), neoplasia detection rate (NDR) and total lesion detection yield. Multivariable regression models and inverse probability weighting (IPW) analysis were used to evaluate detection rates taking into consideration recognised variables that associate with dysplasia risk. Findings: We included 3643 colonoscopies in 2831 patients (UC 54%, CD 22%, PSC-IBD 24%). The most frequently used modality was WLE (50%) followed by DCE (35%) and VCE (15%), with inter-centre variation in modality selection, dedicated surveillance lists, and withdrawal time. Raw DDR were higher with DCE (10%) and VCE (10%) vs. WLE (7%, p=0·012). On multivariable adjustment, modality was not independently associated with DDR. However, when variables were weighted with IPW, there was a numerically higher DDR with VCE (OR 1·60, 95% CI 1.00-2.58; p=0·051). VCE associated with higher NDR allowing the identification of more serrated and hyperplastic lesions. Longer withdrawal time, previous colorectal neoplasia, bowel preparation quality, and surveillance expertise were also associated with increased detection rates, whereas active inflammation had the opposite effect. Interpretation: In this large, multicentre study of clinical practice DCE was not superior to VCE or WLE for dysplasia detection. Identifying patients who will benefit most from surveillance and providing access to dedicated lists performed by experienced endoscopists with sufficient withdrawal time are key to increasing lesion detection in surveillance programmes.

9 October 2026 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
LBLauren C Beck
Lauren C Beck
GYGregory Young
Gregory Young
NWNicola J Wyatt
Nicola J Wyatt
RMRobert J Mulligan
Robert J Mulligan
RLRobert D Lees
Robert D Lees
CLChristopher A Lamb
Christopher A Lamb
Background & Aims: Patient-reported outcomes (PRO) are essential for monitoring disease activity and treatment response in inflammatory bowel disease (IBD). The conventional PRO-2 requires several days of prospective symptom recording, increasing participant burden and attrition in longitudinal research. We evaluated whether a “rapid PRO-2”, using 2 days of data collected retrospectively and prospectively in a single day, could serve as a reliable and pragmatic alternative to a 4-day PRO-2. Methods: Using data from the ongoing IBD-RESPONSE cohort (n = 684 Crohn’s disease [CD]; n = 548 ulcerative colitis [UC]), we compared 4-day PRO-2 and rapid PRO-2 scores at baseline and 14 weeks post-therapy to assess disease activity, clinical (non) response and remission. Results: At baseline, 87.1% (596/684) of CD and 88.7% (486/548) of UC patients remained in the same active/inactive disease activity category (Cohen’s kappa: CD 0.715; UC 0.762; both P < .001). At week 14, 77% (CD; 195/252) and 83.1% (UC; 193/232) remained in the same non-response/response/remission category (Cohen’s kappa: CD 0.653; UC 0.743; both P < .001). Discrepancies mainly involved adjacent category shifts (ie, between response and remission, or non-response and response), with minimal re-classification between remission and non-response (n = 7 CD and n = 2 UC). Greater symptom variability across the 4 days increased the likelihood of switching between remission and non-response (odds ratio [95% confidence interval], CD 5.0 [3.65–6.85]; UC 7.8 [5.6–11.0], both P < .001). Responsiveness to clinical change was comparable between instruments. Conclusions: The rapid PRO-2 retains essential symptom data and demonstrates strong agreement with the 4-day PRO-2, offering an alternative in longitudinal studies to minimize burden and attrition.